Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16459277 | 0.73 | HDAC1 (0.43) | MAPT | |
| SCHEMBL20322515 | 0.69 | KCNH2 (0.45) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL20231005 | 0.69 | KCNH2 (0.45) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL7243686 | 0.69 | KCNH2 (0.45) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL1366894 | 0.67 | ALDH1A1 (0.55) | MAPTTDP1LMNAALDH1A1HTT | |
| SCHEMBL16459236 | 0.66 | MAPT (0.33) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL21025630 | 0.65 | MAPT (0.35) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL25900772 | 0.65 | MAP3K12 (0.38) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL25890068 | 0.65 | DRD3 (0.44) | MAPTNPSR1TDP1LMNAL3MBTL1 | |
| SCHEMBL14768030 | 0.64 | MMP13 (0.50) | MAPTTDP1LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | MAPT 3745/4885NPSR1 2599/4885TDP1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.